查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198378

智能药丸药物输送市场-增长、趋势、COVID-19 影响和预测 (2023-2028)

Smart Pills Drug Delivery Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，智能药丸给药市场预计将以 10.2% 的复合年增长率增长。

COVID-19 大流行增加了对智能药丸的需求，以管理患有 COVID-19 和其他相关疾病的患者。 它还刺激了开发智能药物的研发活动。 例如，根据 2020 年 8 月发表在 International Journal on Emerging Technologies 上的一篇文章，在 COVID-19 大流行的时代，越来越需要老年人和感染者使用预编程的药丸给药系统。需要发展。 这里提出的预编程药丸分配器 (PPD) 就是这样一种方法，旨在让用户定期服药。 所提出的预编程给药系统设计有使用警报和摄像头单元的警告模块。 这是旨在帮助患者定期服药的方法之一，而发展中国家的家庭保健成本要高得多，这使得个人寻求具有成本效益的解决方案。据说这是一个导火索。 因此，据观察，所研究的市场受到上述因素的积极影响。

推动智能药丸给药市场增长的某些因素包括对微创设备的偏好增加、胃肠道疾病发病率增加以及技术进步。 此外，神经系统疾病、癌症和其他疾病日益加重的负担正在推动医疗环境中对智能平板电脑的需求。 例如，根据世界卫生组织 2021 年 9 月更新，约有 5500 万人患有痴呆症，其中超过 60% 生活在低收入和中等收入国家。 同一份文件还报告说，这一数字预计到 2030 年将增加到 7800 万，到 2050 年将增加到 1.39 亿。 随着阿尔茨海默病和痴呆患者的增加，忘记吃药或误服的可能性越来越大，对智能药丸和药物输送的需求越来越大。 因此，全球不断增加的疾病负担和日益增长的护理需求正在推动市场研究。

根据 GIE Media Co., Ltd. 2021 年 12 月发表的一篇文章，需要使用特殊工具来执行需要高级技能的动作，这些工具的可见性和运动范围有限，因此手术团队引入了更高水平的的专业知识。 辅助设备包括内窥镜照相机、可视化扫描仪和造影剂注射器。 根据 2020 年 1 月发表在 JAMA Network 上的一篇论文，由于与传统开放手术技术相比具有优势，大多数外科医生现在更喜欢高度微创的手术，例如腹腔镜单切口手术 (LESS)，从而选择手术技术。 这些好处包括更少的疤痕和组织损伤、更快的恢復、更短的住院时间、更少的出血和创伤、更低的感染风险以及更低的整体医疗保健成本。 此外，在一些国家，医疗保险越来越多地涵盖微创手术。 这些因素增加了患者对微创手术的偏好，导致智能药丸给药市场的增长。

因此，上述因素共同归因于所研究的市场在预测期内的增长。 然而，预计在预测期内，批准智能药丸的严格法规和潜在的健康风险将阻碍市场增长。

智能药丸给药市场趋势

分类型来看，胶囊内镜有望占据较大市场份额

胶囊内窥镜检查是一种使用小型无线摄像头拍摄消化道照片的程序。 胶囊内窥镜摄像头装在一个维生素大小的胶囊中，您可以吞嚥。 当胶囊穿过消化道时，相机拍摄了数千张照片并将它们发送到腰带上的记录仪。 随着医疗保健技术的进步，智能药丸可以消除侵入性手术的需要。 在智能药物方面取得了各种进展，例如电池和板载存储器，它们对于长期使用也具有意义。 根据 2022 年 3 月发表在 Gastroenterology & Endoscopy News 上的一篇文章，胶囊内镜在评估 GI 出血方面具有较高的阳性（94%-97%）和阴性（83%-100%）预测价值，内镜检查结果可能导致内镜或手术37% 至 87% 的患者进行干预或改变医疗管理。 因此，由于内窥镜检查领域的不断进步以及胃肠道疾病 (GI) 患病率的增加以及对正确诊断的需求，预计所研究的市场在预测期内将出现快速增长。被认为

由于全球公司倾向于智能胶囊，预计该细分市场将呈现健康增长。 例如，Medtronic 有 PillCam SB1 和 PillCam SB2，Olympus 有 Endocapsule 和 Endocapsule 10，NaviCam Stomach 是 Ankon 开发的，而 CapsoVision 则在全球市场提供 CapsoCam。 市场上的先进技术和产品批准也有望推动该领域的增长。 例如，2021 年 11 月，美敦力公司宣布美国食品和药物管理局 (FDA) 批准用于远程内窥镜手术的 PillCam Small Bowel 3 系统。 此外，2022 年 7 月，苏格兰卫生研究人员将启动一项耗资 600 万欧元的新项目，使人工智能辅助 (AI) 胶囊内窥镜成为未来肠癌诊断的一部分。 临床胶囊内窥镜检查 (CCE) 使用一种包含摄像头的“智能药丸”，当患者吞服该摄像头时，它会记录通过肠道的图像。

因此，上述因素预计将在预测期内推动市场的细分增长。

北美主导市场，预计在预测期内也会如此

由于以下因素，北美占据了全球市场的大部分份额，例如广泛接受先进的解决方案以简化患者护理、庞大的客户群以及快速增长的老年人口。

由于人为干预特殊药物输送而导致的用药错误增加可能会导致快速增长，并且需要专注于为美国患者提供基于价值的护理。 根据国家医学图书馆发表的一篇论文，到 2022 年 7 月，仅在美国，每年将有 7,000 至 9,000 人死于用药错误。 此外，数以百万计的人有他们通常不会透露的副作用和其他药物问题。 根据美国食品和药物管理局 (FDA) 的数据，到 2020 年，美国每年报告的疑似用药错误超过 100,000 起。 因此，这一统计数据表明，该国对智能药丸产品的需求越来越大，以避免用药错误。

根据 2022 年阿尔茨海默病事实与数据报告，超过 600 万各年龄段的美国人患有阿尔茨海默病，到 2022 年，65 岁以上的美国人将有 650 万患有阿尔茨海默病。据估计，一个人与阿尔茨海默氏病。 同一份数据显示，美国65岁及以上总人口中约每9人中就有1人（10.7%）患有阿尔茨海默病，而65至74岁的人中有5.0%随着年龄增长而患阿尔茨海默病。据报导，有的人 因此，从统计数据来看，美国对智能药丸的需求预计会增长。

智能药丸给药市场的竞争对手分析

由于多家公司在全球和区域开展业务，智能药丸给药市场得到了整合。 竞争格局包括 CapsoVision、Check-Cap、etectRx Inc、HQ Inc、金山科技、Koninklijke Philips NV (Medimetrics)、Medtronic PLC、Olympus Medical Technology、Otsuka Pharmaceutical、Proteus Pharmaceuticals、Intermedic 等。包括分析几种高-简介国际和区域公司。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 越来越喜欢微创设备
    • 慢性病发病率增加
    • 技术进步
  • 市场製约因素
    • 智能药丸审批的严格规定
    • 潜在的健康风险
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 类型
    • 胶囊内窥镜检查
    • 病人监护
    • 药物输送系统
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • CapsoVision
    • Check-Cap
    • etectRx Inc.
    • HQ Inc.
    • Jinshan Science and Technology
    • Koninklijke Philips NV（Medimetrics）
    • Medtronic PLC
    • Olympus Medical Technology
    • Otsuka Pharmaceutical Co. Ltd
    • Intromedic

第7章 市场机会与今后动向

简介目录
Product Code: 51919

The Smart Pills Drug Delivery Market is expected to register a CAGR of 10.2% over the forecast period.

The COVID-19 pandemic has boosted the demand for smart pills for managing patients suffering from COVID-19 and other associated disorders. It has also fueled the research and development activities for developing smart drugs. For instance, as per an article published by the International Journal on Emerging Technologies, in August 2020, in times of the COVID-19 pandemic, there was a need to develop a pill drug delivery system with a preprogrammed feature that will be used by the elderly or infected people. The proposed preprogrammed pill dispenser (PPD) is one such approach that is designed to help them to take their medicines at regular intervals of time. It states that the proposed preprogrammed drug delivery system is designed with an alerting module using an alarm and camera unit, which is one such approach intended to help patients take their medications at regular intervals as the in-home medical care cost in a developing country is much higher, which leads the individual to think of a cost-effective solution. Hence, with the abovementioned factors, it is observed that the market studied was positively impacted.

Specific factors driving the smart pills drug delivery market growth include increasing preference for minimally invasive devices, increasing incidence of gastrointestinal disorders, and technological advancements. Additionally, the increasing burden of neurological, cancer and other diseases drives the demand for intelligent pills in healthcare settings. For instance, according to the World Health Organization September 2021 update, around 55 million people have dementia, with over 60% living in low and middle-income countries. The same source also reports that this number is expected to rise to 78 million in 2030 and 139 million in 2050. With the increasing cases of Alzheimer's and dementia, there are increased chances of missing doses of medication or wrong administration of it, increasing the need for smart pills and drug delivery. Thus, the increasing burden of diseases around the globe and the need for care drives the market studied.

According to an article published by GIE Media, Inc., in December 2021, the need to perform highly skilled actions using specialized tools with limited visibility and motion range has introduced higher levels of expertise for surgical teams. Support equipment includes endoscopic cameras, visualization scanners, contrast injectors, etc. According to an article published on JAMA Network in January 2020, most surgeons currently opt for advanced minimally invasive surgical procedures such as laparo-endo single-incision surgery (LESS) due to their advantages over traditional open surgical techniques. These advantages include fewer scars and tissue injury, quicker recovery periods, shorter hospital stays, reduced blood loss and trauma, lower risk of infection, and reduced overall healthcare costs. In addition, minimally invasive surgeries are increasingly being covered by health insurance providers in selected countries. These factors have led to an increased preference for minimally invasive surgeries among patients leading to the growth of the smart pills drug delivery market.

Therefore, the abovementioned factors are attributed collectively to the studied market growth over the forecast period. However, stringent regulations for approving smart pills and potential health risks are expected to hinder market growth over the forecast period.

Smart Pills Drug Delivery Market Trends

Capsule Endoscopy is Expected to Hold Significant Market Share in the Type Segment

Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures transmitted to a recorder you wear on a belt around your waist. With the advent of healthcare technology, smart pills can eliminate the need for invasive procedures. Various advances are being undertaken in smart drugs, such as batteries and onboard memory, making them significant for long-term usage. According to an article published by Gastroenterology & Endoscopy News in March 2022, capsule endoscopy has a high positive (94%-97%) and negative (83%-100%) predictive value in the evaluation of GI bleeding, and findings on capsule endoscopy can lead to endoscopic or surgical intervention or a change in medical management in 37% to 87% of patients. Hence, with the continuous advancements that are being made in the area of endoscopy, and with the rising in gastrointestinal disorders (GI) and the need for proper diagnosis, it is believed that the market studied will have rapid growth over the forecast period.

The segment is expected to witness healthy growth due to the global companies inclining toward the smart capsule. For instance, Medtronic provides PillCam SB1 and PillCam SB2, Olympus provides Endocapsule and Endocapsule 10, NaviCam Stomach is developed by Ankon, whereas, CapsoVision provides CapsoCam in the global markets. Advanced technologies and product approvals in the market are also expected to drive segment growth. For instance, In November 2021, Medtronic plc announced the United States Food and Drug Administration (FDA) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures. Additionally, in July 2022, Scottish health researchers launched a new EUR 6 million project to make Artificial Intelligence-assisted (AI) capsule endoscopy a part of future bowel cancer diagnostics. Clinical Capsule Endoscopy (CCE) utilizes a 'smart pill' containing cameras that, once swallowed by a patient, records images of the intestines as it passes through.

Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America has dominated the global market studied, owing to the factors, such as the wide acceptance of technologically advanced solutions to make patient care hassle-free, a large pool of customers, and a rapidly growing geriatric population.

A growing number of medication errors due to human intervention in specialty drug delivery may result in steep upward growth, which requires the need to focus on providing value-based care to patients in the United States. As per an article published by the National Library of Medicine, in July 2022, 7,000 to 9,000 persons each year in the United States alone die as a result of drug mistakes. Additionally, millions of additional people have adverse reactions or other pharmaceutical issues but frequently fail to disclose them. According to the United States Food and Drug Administration (FDA), in 2020, it was found that every year more than 100,000 cases of suspected medication errors are reported in the United States. Thus, the statistics indicate that there has been a rising need for smart pill products in the country to avoid medication errors.

As per the 2022 Alzheimer's Disease facts and figures report, more than 6 million Americans of all ages have Alzheimer's and an estimated 6.5 million Americans aged 65 and older are living with Alzheimer's in 2022. The same source reports that out of the total US population, about 1 in 9 people (10.7%) age 65 and older has Alzheimer's dementia and the percentage of people with Alzheimer's dementia increases with age, 5.0% of people aged 65 to 74. Thus, the statistics indicate that the demand for smart pills is expected to rise in the United States.

Smart Pills Drug Delivery Market Competitor Analysis

The Smart Pills Drug Delivery market is consolidated due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including CapsoVision, Check-Cap, etectRx Inc., HQ Inc., Jinshan Science and Technology, Koninklijke Philips NV (Medimetrics), Medtronic PLC, Olympus Medical Technology, Otsuka Pharmaceutical Co. Ltd, Proteus Pharmaceuticals, and Intromedic, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Preference for Minimally Invasive Devices
    • 4.2.2 Increasing Incidence of Chronic Disorders
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations for the Approval of Smart Pills
    • 4.3.2 Potential Health Risk
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type
    • 5.1.1 Capsule Endoscopy
    • 5.1.2 Patient Monitoring
    • 5.1.3 Drug and Delivery Systems
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 CapsoVision
    • 6.1.2 Check-Cap
    • 6.1.3 etectRx Inc.
    • 6.1.4 HQ Inc.
    • 6.1.5 Jinshan Science and Technology
    • 6.1.6 Koninklijke Philips NV (Medimetrics)
    • 6.1.7 Medtronic PLC
    • 6.1.8 Olympus Medical Technology
    • 6.1.9 Otsuka Pharmaceutical Co. Ltd
    • 6.1.10 Intromedic

7 MARKET OPPORTUNITIES AND FUTURE TRENDS